AI Stock Analysis - Sarepta Therapeutics (SRPT)
Analysis generated September 29, 2025.
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and gene editing for the treatment of rare and infectious diseases. Founded with an emphasis on Duchenne muscular dystrophy (DMD), the company has built a substantial pipeline, including multiple approved therapies and a range of candidates in various stages of clinical trials. Sarepta's mission is to transform the lives of patients with genetic illnesses by advancing cutting-edge science and medicine.
Stock Alerts - Sarepta Therapeutics (SRPT)
 |
Sarepta Therapeutics | June 2 Price is down by -6% in the last 24h. |
|
Sarepta Therapeutics | May 15 Price is down by -6.2% in the last 24h. |
|
Sarepta Therapeutics | May 7 Price is down by -7.3% in the last 24h. |
|
Sarepta Therapeutics | May 6 Price is up by 6% in the last 24h. |
Download our app on iOS or Android to get future alerts delivered in real-time.
Alternative Data for Sarepta Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 40 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 25,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 279 | Sign up | Sign up | Sign up |
| Facebook Followers | 11,228 | Sign up | Sign up | Sign up |
| Instagram Followers | 6,364 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 345 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 26,654 | Sign up | Sign up | Sign up |
| X Followers | 6,571 | Sign up | Sign up | Sign up |
| X Mentions | 2 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $77,000 | Sign up | Sign up | Sign up |
| Business Outlook | 45 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,159 | Sign up | Sign up | Sign up |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
| Price | $15.77 |
| Target Price | Sign up |
| Volume | 2,270,569 |
| Market Cap | $1.62B |
| Year Range | $15 - $24.45 |
| Dividend Yield | 0% |
| PE Ratio | 43.74 |
| Analyst Rating | 95% buy |
| Industry | Biotechnology |
In the news
 |
Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20 - Yahoo Entertainment |
Amondys 45 (casimersen: Sarepta Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035FMarch 13 - GlobeNewswire |
|
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta TherapeuticsMarch 2 - GlobeNewswire |
|
Sarepta Therapeutics Launches ELEVIDYS Gene Therapy In Japan For Children With Duchenne Muscular Dystrophy; Co Eligible To Receive A $40M Milestone Payment Upon First Commercial Sale In JapanFebruary 23 - Benzinga |
|
 |
Does Sarepta’s Move Into Huntington’s siRNA Trials Reframe the Bull Case For Sarepta Therapeutics (SRPT)?February 13 - Yahoo |
|
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price VolatilityFebruary 13 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '26 | 731M | 119M | 611M | 331M | 372M | 3.160 |
| Q4 '25 | 443M | 399M | 44M | -283M | -252M | -3.580 |
| Q3 '25 | 399M | 151M | 249M | -180M | -168M | -0.130 |
| Q2 '25 | 611M | 153M | 459M | 197M | 170M | 2.020 |
| Q1 '25 | 745M | 138M | 607M | -448M | -369M | -3.420 |
Insider Transactions View All
| Mayo Stephen filed to sell 1,765 shares at $17. March 13 '26 |
| Estepan Ian Michael filed to sell 193,300 shares at $22.3. December 18 '25 |
| Nicaise Claude filed to sell 27,812 shares at $99.6. March 13 '25 |
| Wigzell Hans Lennart Rudolf filed to sell 22,840 shares at $124.8. December 16 '24 |
| Boor Kathryn Jean filed to sell 5,880 shares at $125.6. December 6 '24 |
Similar companies
Read more about Sarepta Therapeutics (SRPT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Sarepta Therapeutics
The Market Cap of Sarepta Therapeutics is $1.62B.
As of today, Sarepta Therapeutics' PE (Price to Earnings) ratio is 43.74.
Currently, the price of one share of Sarepta Therapeutics stock is $15.77.
The SRPT stock price chart above provides a comprehensive visual representation of Sarepta Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sarepta Therapeutics shares. Our platform offers an up-to-date SRPT stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Sarepta Therapeutics (SRPT) does not offer dividends to its shareholders. Investors interested in Sarepta Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Sarepta Therapeutics are Gilead Sciences, Inovio Pharmaceuticals, Anavex Life Sciences, BridgeBio Pharma, and Crispr Therapeutics.
